STOCK TITAN

Lakewood-Amedex faces Nasdaq delisting over $1 rule

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Lakewood-Amedex Biotherapeutics Inc. received notice that Nasdaq Staff had determined to delist its securities after the common stock’s closing bid price stayed below the $1.00-per-share minimum for 30 consecutive business days, from September 29 through November 9, 2026. Because the company effected a 1-for-10 reverse stock split on June 22, 2026, within the prior year, it is ineligible for a compliance period.

Unless the company requests a hearing by November 17, 2026, trading is scheduled to be suspended at the opening of business on November 19, 2026, and Nasdaq will file to remove the securities from listing and registration. The company intends to request a hearing, which would stay the suspension and filing pending the Panel’s decision. Its compliance plan may include another reverse stock split; there is no assurance the Panel will permit continued listing or that the company will regain compliance.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointNasdaq Staff determined to delist LABT after 30 business days below the $1.00 bid-price minimum.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Minimum closing bid price $1.00 per share Nasdaq continued-listing minimum under the Bid Price Rule
Below-minimum period 30 consecutive business days September 29 through November 9, 2026
Prior reverse stock split 1-for-10 Effected June 22, 2026; cited in connection with ineligibility for a compliance period
Hearing request deadline November 17, 2026 The company intends to request a hearing by this deadline
Potential trading suspension November 19, 2026 Suspension would begin at the opening of business if the company does not request a hearing by the deadline
Bid Price Rule regulatory
"minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"
compliance period regulatory
"the Company is not eligible for a compliance period"
A compliance period is a defined stretch of time during which a company must meet specific legal, regulatory, or contractual rules and reporting requirements. Think of it like a scheduled inspection window or a homework deadline: failing to satisfy the rules within that window can trigger fines, restrictions, or extra oversight, so investors watch compliance periods as signals of near-term legal risk, potential costs, and impacts on a company’s operations or cash flow.
Nasdaq Hearings Panel regulatory
"request a hearing before a Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
Form 25-NSE regulatory
"Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission"
Form 25‑NSE is an official filing used to notify the stock exchange that a company’s securities are being removed from trading on that exchange, similar to handing in a key when a shop closes. Investors care because removal ends public trading on that venue, often cutting liquidity and making it harder to buy or sell shares, which can affect a stock’s price and how quickly investors can access cash or exit positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Nasdaq determine to delist LABT?

Nasdaq Staff cited the common stock’s closing bid price below the $1.00-per-share minimum for 30 consecutive business days, from September 29 through November 9, 2026. The company is ineligible for a compliance period because it effected a 1-for-10 reverse stock split on June 22, 2026, within the prior year.

When could LABT trading be suspended?

Trading could be suspended at the opening of business on November 19, 2026, unless the company requests a hearing by November 17, 2026. The company intends to request a hearing, which would stay the suspension and Nasdaq’s Form 25-NSE filing pending the Panel’s decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0002079272 0002079272 2026-11-10 2026-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 10, 2026

 

 

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-43239   20-5274304
(State or other jurisdiction
of incorporation)
  (Commission File Number)  

(IRS Employer

Identification No.)

 

8031 Cooper Creek Blvd., Unit 103, University Park, Florida 34201

(Address of principal executive offices) (Zip Code)

 

(941) 225-2515

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   LABT   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On November 10, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from September 29, 2026 through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

 

Because the Company effected a 1-for-10 reverse stock split on June 22, 2026, within the prior one-year period, the Company is not eligible for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv), and the Staff has determined to delist the Company’s securities. Unless the Company requests a hearing by November 17, 2026, trading of the Company’s common stock will be suspended at the opening of business on November 19, 2026, and Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq.

 

The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”), which will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. At the hearing, the Company intends to present a plan to regain compliance with the Bid Price Rule, which may include a reverse stock split. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to request a hearing, the outcome of any hearing, and the Company’s plans to regain compliance with the Bid Price Rule. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that the Panel may not grant the Company’s request for continued listing, that a reverse stock split may not result in compliance with the Bid Price Rule, and that the Company’s common stock may be delisted from Nasdaq, as well as those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.
     
Date: November 16, 2026 By: /s/ Kelvin Cooper
  Name: Kelvin Cooper
  Title: Chief Executive Officer

 

2

 

Filing Exhibits & Attachments

3 documents

Keep reading